Eva Renee Barnett is Chief Financial Officer of Immunovant, Inc.. Currently has a direct ownership of 335,343 shares of IMVT, which is worth approximately $9.23 Million. The most recent transaction as insider was on Oct 16, 2024, when has been sold 3,271 shares (Common Stock) at a price of $28.79 per share, resulting in proceeds of $94,172. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 335K
3.51% 3M change
1.34% 12M change
Total Value Held $9.23 Million

Eva Renee Barnett Transaction History

Date Transaction Value Shares Traded Shares Held Form
Oct 16 2024
SELL
Open market or private sale
$94,172 $28.79 p/Share
3,271 Reduced 0.97%
335,343 Common Stock
Oct 09 2024
SELL
Open market or private sale
$152,588 $29.56 p/Share
5,162 Reduced 1.5%
338,614 Common Stock
Aug 21 2024
SELL
Open market or private sale
$120,877 $32.08 p/Share
3,768 Reduced 1.08%
343,776 Common Stock
Jul 17 2024
SELL
Open market or private sale
$93,971 $30.09 p/Share
3,123 Reduced 0.89%
347,544 Common Stock
Jul 09 2024
SELL
Open market or private sale
$133,200 $28.06 p/Share
4,747 Reduced 1.34%
350,667 Common Stock
May 22 2024
SELL
Open market or private sale
$119,845 $29.65 p/Share
4,042 Reduced 1.12%
355,414 Common Stock
Apr 17 2024
SELL
Open market or private sale
$359,870 $29.37 p/Share
12,253 Reduced 3.3%
359,456 Common Stock
Apr 09 2024
SELL
Open market or private sale
$115,023 $31.18 p/Share
3,689 Reduced 0.98%
371,709 Common Stock
Apr 02 2024
BUY
Grant, award, or other acquisition
-
54,978 Added 12.77%
375,398 Common Stock
Feb 22 2024
SELL
Open market or private sale
$105,919 $36.15 p/Share
2,930 Reduced 0.91%
320,420 Common Stock
Jan 11 2024
SELL
Open market or private sale
$147,770 $42.04 p/Share
3,515 Reduced 1.08%
323,350 Common Stock
Nov 22 2023
SELL
Open market or private sale
$134,382 $33.14 p/Share
4,055 Reduced 1.23%
326,865 Common Stock
Oct 10 2023
SELL
Open market or private sale
$168,244 $36.92 p/Share
4,557 Reduced 1.36%
330,920 Common Stock
Aug 24 2023
SELL
Open market or private sale
$296,207 $20.59 p/Share
14,386 Reduced 4.11%
335,477 Common Stock
Jul 19 2023
SELL
Open market or private sale
$67,961 $24.94 p/Share
2,725 Reduced 0.77%
349,863 Common Stock
Apr 18 2023
SELL
Open market or private sale
$52,269 $15.27 p/Share
3,423 Reduced 0.96%
352,588 Common Stock
Apr 12 2023
BUY
Grant, award, or other acquisition
-
87,664 Added 19.76%
356,011 Common Stock
Jan 11 2023
SELL
Open market or private sale
$71,934 $15.95 p/Share
4,510 Reduced 1.65%
268,347 Common Stock
Oct 11 2022
SELL
Open market or private sale
$118,000 $9.44 p/Share
12,500 Reduced 4.38%
272,857 Common Stock
Aug 17 2022
BUY
Grant, award, or other acquisition
-
112,816 Added 28.33%
285,357 Common Stock
Jan 07 2022
SELL
Open market or private sale
$217,203 $7.25 p/Share
29,959 Reduced 14.79%
172,541 Common Stock
Oct 15 2021
BUY
Grant, award, or other acquisition
-
143,000 Added 41.39%
202,500 Common Stock
Oct 04 2021
BUY
Grant, award, or other acquisition
-
59,500 Added 50.0%
59,500 Common Stock
ERB

Eva Renee Barnett

Chief Financial Officer
New York, NY

Track Institutional and Insider Activities on IMVT

Follow Immunovant, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells IMVT shares.

Notify only if

Insider Trading

Get notified when an Immunovant, Inc. insider buys or sells IMVT shares.

Notify only if

News

Receive news related to Immunovant, Inc.

Track Activities on IMVT